The HCPLive conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.
Carl D. Regillo, MD: Key Factors of Faricimab In Neovascular AMD Treatment
Dr. Regillo discusses the efficacy and durability of faricimab for wet AMD treatment in TENAYA and LUCERNE, showing noninferiority to aflibercept.
Rishi P. SIngh, MD: Advances and Challenges in Neovascular AMD Treatment
Dr. Singh discusses the aging population in ophthalmology care, advances including port delivery systems, and the potential rapid uptake of faricimab in treatment.
US Patient Access to Ophthalmology Clinical Trial Sites Differs by Regions
A geographical study shows patients in areas with lower income, education, and higher rates of ophthalmic disease may be a greater distance from a trial site.
Rishi P. SIngh, MD: Durability of Faricimab in Neovascular AMD Treatment
Dr. Singh discusses results from TENAYA and LUCERNE on faricimab compared to afilbercept in patients with nAMD.
Ranibizumab Biosimilar FYB201 Provides Similar Efficacy, Safety in Phase 3 Trial
The COLUMBUS-AMD trial suggests the investigative biosimilar could benefit patients newly diagnosed with nAMD.
New Model Could Predict Cost of PDR Prevention with Aflibercept
A cost-based assessment of Protocol W and PANORAMA clinical data suggests diabetic retinopathy may be less costly to prevent than macular edema.
Paul Sternberg, MD: Perspectives on Step Therapy in Wet AMD Treatment
Dr. Sternberg discusses step therapy in wetAMD treatment and his opinions in favor of its use.
Bevacizumab Formulation Significantly Improves wAMD Vision Versus Ranibizumab in NORSE 2
Bevacizumab-vikg was associated with statistically significant improvements in patient BCVA scores over a period of 12 months, according to phase 3 findings.
Treat-and-Extend for Anti-VEGF May Provide More Optimal Dosing and Fewer Clinic Visits
A meta-analysis comparison of dosing regimens for patients with nAMD show little difference in efficacy, but differences in patient involvement in care.
Vorolanib via Durasert Provides Safe Treatment of Wet AMD Through 12 Months
A phase 1 trial of the investigative drug suggests its promise in a novel strategy of managing patients with retinal fluid.
David R. Lally, MD: Analyzing Nascent GA, Intermediate AMD Progression from GATHER1
Dr. Lally discusses the effect of avacincaptad pegol treatment on the progression of geographic atrophy and intermediate age-related macular degeneration.
Gene Therapy ADVM-022 Provides Mixed Efficacy, Safety in Treating DME
Findings from the phase 2 INFINITY suggest a more dose-dependent influence on safety outcomes in patients receiving sustained benefit for diabetic macular edema.
Optogenetics Product Provides Safe Treatment Opportunity for Retinitis Pigmentosa Reversal
An update from the PIONEER trial shows the combination gene therapy and medical device strategy is safe and tolerable, while providing cases of improved light perception.
Julia A Haller, MD: Facing Challenges and Finding Solutions in Retina
Dr. Haller discusses issues in diversity and inclusion in retina, but provides avenues for solutions and what needs to come next.
Dosing Variability Risk Could Be High With Aflibercept PFS
An AAO 2021 presentation highlighted the industrial design differences that could result in treatment overdoses with pre-filled syringes of aflibercept.
COVID-19 Lockdowns Drove Fewer Anti-VEGF Injections, Worse Vision in Ophthalmic Patients
Early 2020 response to the pandemic was linked to many patients being lost to follow-up, and countries reported worse overall visual acuity among their patients.
Reduced Retinal Fluid Linked to Better nAMD Visual Improvements
New HAWK and HARRIER findings show patients with fluid-free visits reported greater benefit in BVCA while receiving anti-VEGF.
Patient B-Cell Counts at Time of Vaccine Influence COVID-19 Antibody Response
Patients who are treated with B cell depletion therapies show that their B cell count at time of vaccination can impact their COVID-19 antibody response.
Inflammatory Rheumatic Disease Linked to Reduced mRNA COVID-19 Vaccine Response
An assessment of a rheumatic disease cohort shows Spike protein antibody response is significantly decreased in vaccinated patients, and may vary by treatment.
Mithu Maheswaranathan, MD, Speaks About Low Health Literacy in SLE Patients
Lower health literacy has been found to be associated with worsened health outcomes for patients with systemic lupus erythematosus (SLE).
Adverse Pregnancy Outcomes Remain Significant in Women with Systemic Sclerosis
Fetal deaths associated with the rheumatic disease have been on the decline, but increased risks persist nonetheless.
Women, Alcohol Drinkers Are at Greater Risk of Methotrexate Side Effects
Alopecia and nausea risk may be more easily identified in patients initiating methotrexate for rheumatoid arthritis.
Jonathan Vela, MD: CBD Shows No Effect in Patients with Chronic Pain
A study presented at ACR 2021 found that CBD had no significant effect on pain intensity in patients with hand osteoarthritis or psoriatic arthritis.
Guselkumab Safety Remains Consistent in Psoriasis, Psoriatic Arthritis
An assessment of data from the DISCOVER and VOYAGE trials show the IL-23 inhibitor provides similar safety profiles in patients with either psoriatic disease.
Romosozumab FDA Label May Have Reduced Cardiovascular Risks in Osteoporosis Patients
Interim data from a post-marketing analysis suggest a boxed label warning for the drug in 2019 may have limited high-risk patients taking the biologic therapy.
Pediatric Arthritis Linked to Households with Lower Income, Education
A cross-sectional analysis suggests patients with worse social risk scores are significantly more likely to be impacted by juvenile idiopathic arthritis.
Nathan den Broeder, MSs: Finding the Right Dose of Rituximab for Rheumatoid Arthritis
This study shows that many patients with rheumatoid arthritis can use a dose lower than 1000mg and still see results.
Jonathan Vela, MD, Decides it's Time to Examine CBD Treatment for Chronic Pain
With the popularity of CBD growing in Denmark, Jonathan Vela, MD, examined the effectiveness of CBD treatment on hand osteoarthritis and psoriatic arthritis.
Rituximab Linked to Worse COVID-19 Vaccine Response than Immunosuppressants
More data from ACR 2021 evidences the risk of minimal response to mRNA vaccines in autoimmune disorder patients on rituximab.
Jing Cui, PhD, Discusses Next Steps for Risk Prediction Models for SLE
In this video interview, Dr. Jing Cui explains what the next steps could be for the risk prediction models of systemic lupus erythematosus.